BG104730A - Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems - Google Patents
Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systemsInfo
- Publication number
- BG104730A BG104730A BG104730A BG10473000A BG104730A BG 104730 A BG104730 A BG 104730A BG 104730 A BG104730 A BG 104730A BG 10473000 A BG10473000 A BG 10473000A BG 104730 A BG104730 A BG 104730A
- Authority
- BG
- Bulgaria
- Prior art keywords
- formula
- naoh
- koh
- produced
- strong base
- Prior art date
Links
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 abstract 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical group CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 abstract 2
- 239000000010 aprotic solvent Substances 0.000 abstract 2
- 239000003054 catalyst Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 abstract 1
- 150000001491 aromatic compounds Chemical class 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000010438 heat treatment Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 239000012299 nitrogen atmosphere Substances 0.000 abstract 1
- 229910052763 palladium Inorganic materials 0.000 abstract 1
- 239000008188 pellet Substances 0.000 abstract 1
- 239000003444 phase transfer catalyst Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 125000001453 quaternary ammonium group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 230000001052 transient effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Pyridine Compounds (AREA)
- Catalysts (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15161099P | 1999-08-31 | 1999-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG104730A true BG104730A (en) | 2001-09-28 |
Family
ID=22539510
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG104730A BG104730A (en) | 1999-08-31 | 2000-08-29 | Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems |
Country Status (33)
| Country | Link |
|---|---|
| EP (1) | EP1081144A3 (cs) |
| JP (1) | JP2001106686A (cs) |
| KR (1) | KR20010050274A (cs) |
| CN (1) | CN1286251A (cs) |
| AP (1) | AP2000001909A0 (cs) |
| AR (1) | AR022650A1 (cs) |
| AU (1) | AU5370200A (cs) |
| BG (1) | BG104730A (cs) |
| BR (1) | BR0003888A (cs) |
| CA (1) | CA2316748A1 (cs) |
| CO (1) | CO5180623A1 (cs) |
| CZ (1) | CZ20003159A3 (cs) |
| EA (1) | EA200000803A3 (cs) |
| EE (1) | EE200000513A (cs) |
| GT (1) | GT200000144A (cs) |
| HR (1) | HRP20000565A2 (cs) |
| HU (1) | HUP0003437A3 (cs) |
| ID (1) | ID27128A (cs) |
| IL (1) | IL138089A0 (cs) |
| IS (1) | IS5604A (cs) |
| MA (1) | MA26750A1 (cs) |
| NO (1) | NO20004312L (cs) |
| NZ (1) | NZ506633A (cs) |
| OA (1) | OA11451A (cs) |
| PA (1) | PA8499601A1 (cs) |
| PE (1) | PE20010523A1 (cs) |
| PL (1) | PL342280A1 (cs) |
| SG (1) | SG87145A1 (cs) |
| SK (1) | SK12862000A3 (cs) |
| SV (1) | SV2002000160A (cs) |
| TN (1) | TNSN00176A1 (cs) |
| TR (1) | TR200002530A2 (cs) |
| UY (1) | UY26315A1 (cs) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1627644A4 (en) * | 2003-05-23 | 2012-01-18 | Hisamitsu Pharmaceutical Co | PREPARATION FOR EXTERNAL PERCUTANEOUS ADMINISTRATION WITH AN NON-TEROIDAL INFLAMMATORY MEDICAMENT AND AN INTERLEUKIN 1A PRODUCTION INHIBITOR |
| EP1834953A1 (en) * | 2006-03-14 | 2007-09-19 | Ranbaxy Laboratories Limited | Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors |
| CN103980312B (zh) * | 2014-05-27 | 2016-09-07 | 广州大学 | 一种n杂环双膦配体及其合成方法 |
| WO2025038927A1 (en) * | 2023-08-16 | 2025-02-20 | Raythera, Inc. | Modulators of tnf alpha activity and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK281577B6 (sk) * | 1994-10-18 | 2001-05-10 | Pfizer Inc. | Heterocyklické zlúčeniny a farmaceutický prostriedok na ich báze |
-
2000
- 2000-08-01 SG SG200004340A patent/SG87145A1/en unknown
- 2000-08-10 PA PA20008499601A patent/PA8499601A1/es unknown
- 2000-08-11 CO CO00060138A patent/CO5180623A1/es not_active Application Discontinuation
- 2000-08-17 EP EP00307046A patent/EP1081144A3/en not_active Withdrawn
- 2000-08-18 OA OA1200000224A patent/OA11451A/en unknown
- 2000-08-24 IL IL13808900A patent/IL138089A0/xx unknown
- 2000-08-24 TN TNTNSN00176A patent/TNSN00176A1/fr unknown
- 2000-08-25 IS IS5604A patent/IS5604A/is unknown
- 2000-08-25 SK SK1286-2000A patent/SK12862000A3/sk unknown
- 2000-08-28 UY UY26315A patent/UY26315A1/es not_active Application Discontinuation
- 2000-08-28 ID IDP20000710A patent/ID27128A/id unknown
- 2000-08-29 CA CA002316748A patent/CA2316748A1/en not_active Abandoned
- 2000-08-29 PE PE2000000886A patent/PE20010523A1/es not_active Application Discontinuation
- 2000-08-29 AU AU53702/00A patent/AU5370200A/en not_active Abandoned
- 2000-08-29 GT GT200000144A patent/GT200000144A/es unknown
- 2000-08-29 AR ARP000104489A patent/AR022650A1/es not_active Application Discontinuation
- 2000-08-29 BG BG104730A patent/BG104730A/xx unknown
- 2000-08-30 MA MA26053A patent/MA26750A1/fr unknown
- 2000-08-30 HU HU0003437A patent/HUP0003437A3/hu unknown
- 2000-08-30 CZ CZ20003159A patent/CZ20003159A3/cs unknown
- 2000-08-30 CN CN00126409A patent/CN1286251A/zh active Pending
- 2000-08-30 KR KR1020000050877A patent/KR20010050274A/ko not_active Abandoned
- 2000-08-30 NZ NZ506633A patent/NZ506633A/en unknown
- 2000-08-30 HR HR20000565A patent/HRP20000565A2/hr not_active Application Discontinuation
- 2000-08-30 NO NO20004312A patent/NO20004312L/no not_active Application Discontinuation
- 2000-08-30 SV SV2000000160A patent/SV2002000160A/es unknown
- 2000-08-30 BR BR0003888-1A patent/BR0003888A/pt not_active IP Right Cessation
- 2000-08-31 EE EEP200000513A patent/EE200000513A/xx unknown
- 2000-08-31 EA EA200000803A patent/EA200000803A3/ru unknown
- 2000-08-31 JP JP2000262200A patent/JP2001106686A/ja active Pending
- 2000-08-31 AP APAP/P/2000/001909A patent/AP2000001909A0/en unknown
- 2000-08-31 TR TR2000/02530A patent/TR200002530A2/xx unknown
- 2000-08-31 PL PL00342280A patent/PL342280A1/xx not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Irving et al. | 637. The stability of transition-metal complexes | |
| Jaganyi et al. | Controlling the Lability of Square-Planar Pt (II) Complexes through Electronic Communication between pi-Acceptor Ligands This work was supported by the Deutsche Forschungsgemeinschaft, Fonds der Chemischen Industrie, and the Alexander von Humboldt Foundation (fellowship to DJ) | |
| EP1026222A3 (en) | Organic material for electroluminescent device and electroluminescent device using the same | |
| Lang et al. | Bis (alkynyl) transition metal complexes, R1C C[M] C CR2, as organometallic chelating ligands; formation of μ, η1 (2)-alkynyl-bridged binuclear and oligonuclear complexes | |
| AU2187001A (en) | Process for preparing ambient temperature ionic liquids | |
| HUP0202597A2 (en) | Mixture of two particulate phases used in the production of a green compact that can be sintered at higher temperatures | |
| GB1490306A (en) | 3-amino-indazolecarboxylic acid derivatives process for their preparation and their use as medicaments | |
| DK1399256T3 (da) | Fremgangsmåde til aktivering af en katalysator omfattende en koboltforbindelse og en bærer | |
| BG105035A (en) | Method for preparing alkoxyamines from nitroxides | |
| AU2576202A (en) | Preparation of polymerization catalysts | |
| Gambs et al. | Ligand Electronic Effect in Enantioselective Palladium-Catalyzed Copolymerization of Carbon Monoxide and Propene This work was supported by the ETH Zürich. We thank Novartis AG and Solvias AG, Basel, for the donation of chemicals | |
| PL320138A1 (en) | Method of and solution for obtaining a conversive coating on metal surface | |
| SE9401150L (sv) | Sätt att framställa belagt hårdämnespulver | |
| BG104730A (en) | Method for producing 5-lipooxygenase inhibitors having different heterocyclic ring systems | |
| Peris et al. | d0 and d2 Polyhydrides as unconventional proton acceptors in lntermolecular hydrogen bonding | |
| ES2113148T3 (es) | Mezcla gasogena. | |
| EP1285902A4 (en) | TRITIUM MARKING PROCESS | |
| IL114676A (en) | Methods for preparing multicarbide powders for hard materials | |
| WO1999010315A3 (de) | Verfahren zur herstellung von 2-cyanoindan-1-onen | |
| Yan et al. | Theoretical explanation for amorphous phase emerging across the interface during explosive welding. | |
| Kandaz et al. | A water-soluble multisite ionophore ligand bearing pyridine and aminothiophenol functionality. Synthesis, spectroscopy and electrochemistry of its complexes, and peripheral reactivity of the (E, E) M (M= Ni) complex with Pd2+ and Ag+ | |
| Alshehri et al. | Leaving group effects on ligand substitution reactions of pentacyanoferrate (II) complexes: rate constant and activation volume correlations | |
| Yamada et al. | Structures and properties of divalent metal complexes of an N2O2 type ligand, 6, 6'-bis (benzoylamino)-2, 2'-bipyridine. | |
| YU52800A (sh) | Postupak za dobijanje inhibitora 5-lipoksigenaze koji imaju različite heterociklične prstenaste sisteme | |
| EP0307179A3 (en) | Mitomycins and processes for their preparation |